Free Trial
→ 9/9 on TSLA from June to January (From Wealthpin Pro) (Ad)

PAVmed Q2 2023 Earnings Report

PAVmed logo
$0.79 +0.01 (+1.51%)
As of 02/21/2025 03:59 PM Eastern
Earnings HistoryForecast

PAVmed EPS Results

Actual EPS
-$1.35
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

PAVmed Revenue Results

Actual Revenue
$0.17 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

PAVmed Announcement Details

Quarter
Q2 2023
Date
8/15/2023
Time
N/A

Conference Call Resources

PAVmed Earnings Headlines

Lucid Diagnostics Executes First Concierge Medicine Contract with LEAA Health
February 20 at 8:31 AM | prnewswire.com
PAVmed regains compliance with Nasdaq equity requirement
February 18, 2025 | markets.businessinsider.com
9/9 on TSLA from June to January
Please take a look at THIS case study on Target (TGT) You’ll see exactly how the tool works to trade long and short, even when the markets seem to be predicting the exact opposite. Now, this tool has been so accurate over recent months that I’m planning to send you 14 more real-world examples of winning trades that anyone using this tool could have captured. And it’s all building to Monday, February 24 @ 1pm ET when I’ll bring the tool to the public for the first time and show you how you can put it on your own charts!
February 22, 2025 | Wealthpin Pro (Ad)
PAVmed Regains Compliance with Nasdaq Stockholders' Equity Requirement
February 18, 2025 | prnewswire.com
Lucid Diagnostics to Participate in the 12th Annual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
February 6, 2025 | prnewswire.com
PAVMed faces Nasdaq delisting over share price rule
January 25, 2025 | msn.com
See More PAVmed Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like PAVmed? Sign up for Earnings360's daily newsletter to receive timely earnings updates on PAVmed and other key companies, straight to your email.

About PAVmed

PAVmed (NASDAQ:PAVM) focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.

View PAVmed Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles